Key result
Platelet glycoprotein IIb/IIIa receptor inhibitors target arterial clot propagation in coronary artery disease where aspirin and ticlopidine have notable failure rates.
Answers are grounded in this paper and cite their sources.
Reviews the role of platelet glycoprotein IIb/IIIa receptor inhibitors as therapeutic targets in coronary artery thrombosis given the failure rates and limitations of aspirin and ticlopidine.
Drugs that dissolve blood clots (thrombolytic agents) and drugs that prevent clot propaga-tion (antiplatelet agents and anticoagulant agents) are used to treat a broad array of cardiovascular diseases. Platelets are a key component of all blood clots propagating within the arterial circulation and thus are an obvious therapeutic target in attempts to inhibit coronary artery thrombosis. However, de-spite evidence that clearly documents the beneficial effects of aspirin over placebo in acute coronary syndromes, many patients still "break through " aspi-rin (1, 2). Ticlopidine, commonly used with aspirin in patients with intracoronary stents (3), has a ben-eficial profile similar to that of aspirin but also has a similar failure rate and a clinically significant as-sociated incidence of leukopenia (4).
No takes yet. Share an insight, caveat, or question.
Marc C. Cohen (1996) conducted a review in Coronary artery disease. Platelet glycoprotein IIb/IIIa receptor inhibitors was evaluated. Platelet glycoprotein IIb/IIIa receptor inhibitors target arterial clot propagation in coronary artery disease where aspirin and ticlopidine have notable failure rates.
Synapse has enriched 10 related papers. Consider them for comparative context: